Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-15 04:18 | 2025-03-12 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Director, Officer | SELL | $44.88 | 1,738 | $78,001 | 654,324 |
| 2025-03-15 03:33 | 2025-03-12 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | Officer | SELL | $44.88 | 607 | $27,242 | 200,540 |
| 2025-03-15 03:30 | 2025-03-12 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Officer | SELL | $44.88 | 614 | $27,556 | 95,034 |
| 2025-03-15 03:24 | 2025-03-12 | AKRO | Akero Therapeutics, Inc. | White William Richard | Officer | SELL | $44.88 | 676 | $30,339 | 61,959 |
| 2025-03-15 03:18 | 2025-03-12 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Officer | SELL | $44.88 | 516 | $23,158 | 169,721 |
| 2025-03-14 23:37 | 2025-03-12 | KNSA | Kiniksa Pharmaceuticals International, plc | Ragosa Mark | Officer | OPT+S | $22.25 | 36,372 | $809,277 | 22,958 |
| 2025-03-14 15:02 | 2025-03-12 | PRLD | Prelude Therapeutics Inc | Vaddi Krishna | Director, Officer | BUY | $0.71 | 97,500 | $69,566 | 1,264,775 |
| 2025-03-15 00:59 | 2025-03-12 | EOLS | Evolus, Inc. | Parschauer Karah Herdman | Director | SELL | $12.99 | 12,888 | $167,465 | 32,183 |
| 2025-03-15 03:03 | 2025-03-14 | ETST | Earth Science Tech, Inc. | Sanchez Yovan Arturo | Director | BUY | $0.12 | 100,000 | $12,000 | 1,606,151 |
| 2025-03-14 23:30 | 2025-03-12 | RPTX | Repare Therapeutics Inc. | Segal Lloyd Mitchell | Director, Officer | SELL | $1.14 | 21,179 | $24,144 | 124,394 |
| 2025-03-14 23:38 | 2025-03-12 | KNSA | Kiniksa Pharmaceuticals International, plc | Megna Michael R | Officer | OPT+S | $22.45 | 9,051 | $203,195 | 26,528 |
| 2025-03-15 01:21 | 2025-03-13 | PTGX | Protagonist Therapeutics, Inc | MOLINA ARTURO MD | Officer | OPT+S | $55.74 | 30,514 | $1,700,850 | 83,892 |
| 2025-03-15 01:20 | 2025-03-12 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | Officer | OPT+S | $58.73 | 24,903 | $1,462,553 | 62,821 |
| 2025-03-14 14:27 | 2025-03-13 | ALT | Altimmune, Inc. | WEAVER GREGORY L | Officer | BUY | $5.20 | 10,000 | $51,996 | 10,000 |
| 2025-03-15 00:30 | 2025-03-12 | ALZN | Alzamend Neuro Inc. | AULT MILTON C III | Director, 10% owner | BUY | $0.68 | 100 | $68 | 77,368 |
| 2025-03-15 00:20 | 2025-03-12 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | Officer | OPT+S | $53.30 | 15,521 | $827,234 | 103,901 |
| 2025-03-15 03:53 | 2025-03-14 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | OPT+S | $45.00 | 100 | $4,500 | 37,663 |
| 2025-03-15 00:28 | 2025-03-13 | ANIP | Ani Pharmaceuticals Inc. | Cook Meredith | Officer | SELL | $63.33 | 400 | $25,332 | 80,545 |
| 2025-03-14 23:25 | 2025-03-12 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | CRAVES FRED B | Director | OPT+S | $328.54 | 15,470 | $5,082,480 | 350,076 |
| 2025-03-14 00:00 | 2025-03-12 | RAPP | Rapport Therapeutics, Inc. | Young Wendy B. | Director | BUY | $10.21 | 6,000 | $61,250 | 6,000 |
| 2025-03-13 23:13 | 2025-03-13 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Officer | SELL | $12.12 | 143 | $1,733 | 96,057 |
| 2025-03-13 23:08 | 2025-03-11 | DYN | Dyne Therapeutics, Inc. | Beskrovnaya Oxana | Officer | SELL | $11.38 | 2,153 | $24,501 | 195,840 |
| 2025-03-13 23:08 | 2025-03-11 | DYN | Dyne Therapeutics, Inc. | Scalzo Richard William | Officer | SELL | $11.38 | 1,343 | $15,283 | 122,330 |
| 2025-03-14 04:40 | 2024-12-30 | VREO | Vireo Growth Inc. | Chicago Atlantic Credit Opportunities, LLC | 10% owner | BUY | $0.62 | 32,222,500 | $20,084,284 | 110,362,683 |
| 2025-03-14 03:00 | 2025-03-12 | SRPT | Sarepta Therapeutics, Inc. | Nicaise Claude | Director | OPT+S | $99.64 | 2,491 | $248,203 | 27,812 |
| 2025-03-14 00:13 | 2025-03-12 | RAPP | Rapport Therapeutics, Inc. | Ignelzi Troy A. | Officer | BUY | $10.10 | 10,000 | $100,988 | 10,000 |
| 2025-03-13 23:17 | 2025-03-13 | LLY | ELI LILLY & Co | Zakrowski Donald A | Officer | SELL | $818.24 | 1,000 | $818,240 | 5,840 |
| 2025-03-13 23:45 | 2025-03-11 | IONS | IONIS PHARMACEUTICALS INC | Monia Brett P | Director, Officer | SELL | $32.32 | 140 | $4,525 | 180,980 |
| 2025-03-14 02:35 | 2025-03-11 | ZYME | Zymeworks Inc. | EcoR1 Capital, LLC | Director, 10% owner | BUY | $12.13 | 1,081,980 | $13,120,955 | 16,802,141 |
| 2025-03-13 23:50 | 2025-03-06 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Dreyer Scott | Officer | SELL | $30.00 | 15,387 | $461,672 | 126,676 |
| 2025-03-13 23:49 | 2025-03-11 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Tupper Colleen | Officer | SELL | $30.01 | 10,445 | $313,413 | 165,246 |
| 2025-03-13 23:01 | 2025-03-11 | GYRE | GYRE THERAPEUTICS, INC. | Ma Songjiang | Director, Officer | SELL | $11.57 | 4,000 | $46,280 | 2,835,260 |
| 2025-03-13 23:30 | 2025-03-13 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | SELL | $43.62 | 26,771 | $1,167,751 | 37,663 |
| 2025-03-13 04:36 | 2025-03-10 | IRON | Disc Medicine, Inc. | Ashiya Mona | Director | SELL | $54.31 | 312,384 | $16,965,606 | 194,209 |
| 2025-03-12 23:10 | 2025-03-10 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Tatsis Ourania | Officer | SELL | $499.99 | 3,242 | $1,620,968 | 51,239 |
| 2025-03-13 01:00 | 2025-03-10 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Director, Officer | SELL | $41.77 | 30,000 | $1,253,070 | 656,062 |
| 2025-03-12 23:37 | 2025-03-10 | KNSA | Kiniksa Pharmaceuticals International, plc | Tessari Eben | Officer | OPT+S | $21.06 | 12,409 | $261,334 | 76,566 |
| 2025-03-12 23:23 | 2025-03-11 | RNA | Avidity Biosciences, Inc. | Flanagan W. Michael | Officer | OPT+S | $30.13 | 20,000 | $602,614 | 91,975 |
| 2025-03-12 23:00 | 2025-03-10 | TRVI | Trevi Therapeutics, Inc. | Simon Farrell | Officer | OPT+S | $6.75 | 81,313 | $548,879 | 76,900 |
| 2025-03-12 23:08 | 2025-03-10 | VRTX | VERTEX PHARMACEUTICALS INC / MA | ALTSHULER DAVID | Officer | SELL | $500.00 | 3,231 | $1,615,500 | 26,512 |
| 2025-03-13 01:13 | 2025-03-12 | EBS | Emergent BioSolutions Inc. | Fowler Neal Franklin | Director | SELL | $5.83 | 35,000 | $204,050 | 101,100 |
| 2025-03-13 01:13 | 2025-03-12 | EBS | Emergent BioSolutions Inc. | Zoon Kathryn C | Director | SELL | $5.73 | 10,000 | $57,300 | 44,482 |
| 2025-03-12 23:51 | 2025-03-10 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Director | BUY | $43.31 | 2,298 | $99,518 | 168,123 |
| 2025-03-12 23:01 | 2025-03-10 | PBH | Prestige Consumer Healthcare Inc. | Fritz Mary Beth | Officer | SELL | $90.00 | 1,678 | $151,020 | 17,157 |
| 2025-03-13 04:44 | 2025-01-10 | CLRB | Cellectar Biosciences, Inc. | Longcor Jarrod | Officer | BUY | $0.28 | 30,000 | $8,400 | 83,141 |
| 2025-03-12 21:24 | 2025-03-10 | JAZZ | Jazz Pharmaceuticals plc | Iannone Robert | Officer | SELL | $138.41 | 2,403 | $332,605 | 79,621 |
| 2025-03-12 23:11 | 2025-03-10 | VRTX | VERTEX PHARMACEUTICALS INC / MA | WAGNER CHARLES F JR | Officer | SELL | $500.00 | 3,298 | $1,649,000 | 51,671 |
| 2025-03-12 23:32 | 2025-03-10 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Dier Mardi | Officer | SELL | $323.04 | 258 | $83,344 | 10,440 |
| 2025-03-12 23:54 | 2025-03-10 | CORT | CORCEPT THERAPEUTICS INC | Swisher Daniel N JR | Director | OPT+S | $53.60 | 2,200 | $117,920 | 0 |
| 2025-03-13 00:20 | 2025-03-10 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | Officer | OPT+S | $53.08 | 75,420 | $4,003,309 | 103,901 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.